Key clinical point: Bimekizumab rapidly improved patient-reported outcomes after the first dose in patients with active psoriatic arthritis (PsA) who were biologic-naive or inadequately responsive to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: At week 4, bimekizumab vs placebo alleviated pain (mean change in Visual Analog Scale score from baseline, −16.0 vs −3.5) and fatigue (mean change in Functional Assessment of Chronic Illness Therapy score from baseline, 3.0 vs 1.0 ; both P < .001). These outcomes, along with improvements in physical function and health-related quality of life, were sustained through week 16 (all P < .001).
Study details: In this post hoc analysis of the phase 3 trials BE OPTIMAL and BE COMPLETE , 1112 patients with PsA who were biologic-naive or TNFi-IR were randomly assigned to receive bimekizumab (n = 698) or placebo (n = 414) .
Disclosures: This study was sponsored by UCB. Five authors declared being employees or shareholders of UCB. Other authors declared having ties with various sources, including UCB.
Source: Husni ME, Mease PJ, Merola JF, et al. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: Pooled 16-week results from two phase 3 studies. RMD Open. 2024;10:e004464. Source